241
First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy
Condition(s):Amyloid Transthyretin CardiomyopathyLast Updated:May 24, 2023Active, not recruiting
First in Human: 7473 Clinical Trials, Page 25 of 748
Hide Studies Not Open or Pending
242
First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects
Condition(s):HealthyLast Updated:January 12, 2022Completed
243
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Condition(s):Solid Tumor; Breast Cancer; Pancreatic Cancer; Ovarian Cancer; Colorectal CancerLast Updated:August 14, 2023Recruiting
244
First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
Condition(s):Safety Issues; Tolerance; Idiopathic Pulmonary Fibrosis; Pulmonary HypertensionLast Updated:March 27, 2023Recruiting
245
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Condition(s):Non-small Cell Lung CancerLast Updated:July 20, 2023Recruiting
246
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
Condition(s):HemophiliaLast Updated:May 5, 2021Terminated
247
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
Condition(s):Immunoglobulin A Nephropathy; IgAN – IgA Nephropathy; IgA NephropathyLast Updated:March 6, 2020Completed
248
CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery
Condition(s):Femoral Artery Stenosis; Popliteal Artery Stenosis; Femoral Artery Occlusion; Popliteal Artery OcclusionLast Updated:February 17, 2023Active, not recruiting
249
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Condition(s):Diffuse Large B-cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell LymphomaLast Updated:September 21, 2023Terminated
250
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Condition(s):PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid TumorLast Updated:May 11, 2023Recruiting